Business Wire

Masimo Partners with Penington Institute to Raise Awareness of Harm from Prescription Opioid Overdose

Share

To mark International Overdose Awareness Day (IOAD) on August 31, Masimo (NASDAQ: MASI), a global medical technology company, announced today its commitment to raising awareness of the risks of overdose from prescription opioids, even when used as directed.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005148/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

August 31 is International Overdose Awareness Day (Photo: Business Wire)

In December 2016, following a routine tonsillectomy, healthy, 21-year-old Parker Stewart took just half of his prescribed dose of opioids and suffered from opioid overdose in his sleep. Tragically, he never woke up. This could have been prevented. His mother, Yvonne Gardner, pleads, “I wish I had known it was a problem – I didn’t know it could happen. I Googled a lot of stuff before the surgery – but I never Googled ‘tonsillectomy fatalities,’ because you just don’t think that such a routine surgery would end up this way.”

Parker’s story is just one example of a preventable death from opioid overdose that happens tens of thousands of times each year around the world.1 Awareness and education are important to helping prevent others. In honor of IOAD, Masimo is launching an educational website, www.OpioidSafety.org, which shares information about the potential side effects of prescription opioid painkillers, who is at risk, and how to protect yourself. Furthermore, Masimo, in partnership with the Penington Institute – the founder of IOAD – has committed to funding comprehensive research and reporting on the prevalence and impact of prescription and non-prescription opioid overdoses. The reports will be made publicly available at no charge, with the first report, focused on the UK, expected to be available in 2022.

In the latest figures for 2020, published by the UK Office for National Statistics (ONS), drug-related deaths recorded in England and Wales reached the highest levels since records began in 1993. Of the 2,263 deaths recorded, approximately half involved opioids.2 Already known to be highly addictive, opioids also have serious side effects, including slowed or stopped breathing – which can lead to cardiac arrest, brain damage, or death.3 Harm can occur even when opioids are taken as prescribed.4

Opioid painkillers are prescribed for pain relief and are commonly used by patients during and after surgery, as well as by those experiencing chronic pain. Opioid prescriptions have increased steadily in the UK, with over 50 million opioid prescriptions written in the UK last year alone.2 Importantly, about 30% of those taking a prescription opioid painkiller don’t realize they’re taking an opioid.5 Last year, more people died from opioids than car accidents.6

Dr. Mike Durkin, a Senior NHS Advisor on Patient Safety Policy and Leadership for the National Institute for Health Research (NIHR) Imperial College Patient Safety Translational Research Centre, said, “Prescription opioids are a cornerstone of pain relief for millions of people recovering from injury or managing medical conditions. However, these treatments can pose serious risks to a person’s health if not monitored continuously, and sometimes result in tragic consequences, including loss of life. It is therefore vital that patients prescribed opioid painkillers have a better understanding of their side effects, and are educated on how to protect themselves, including the role of oxygen saturation (SpO2) monitoring.”

John Ryan, CEO of the Penington Institute, a leader in public health and safety, and immediate past President of London-based Harm Reduction International, said, “Opioid overdose is a complex problem driven by multiple reasons, and as a result, the true scale is not fully reported or understood. However, just because a problem is underreported, it doesn’t mean it doesn’t exist. With incidences of opioid deaths continuing to increase year-on-year, there is an urgent need for better research into treatment and care involving opioids to identify current gaps in care and to help protect people from avoidable harm.”

Joe Kiani, Founder and CEO of Masimo, said, “Too many lives are being lost. Many people immediately assume that an overdose is connected only to the use of illicit drugs or taking more opioids than prescribed. In fact, Parker Stewart took only half the prescribed dose and still died from opioid overdose. We need to prevent harm for anyone taking opioids, including those taking prescription opioids as directed by their healthcare professional for chronic pain or for postoperative or acute pain. We have an obligation to drive education and innovation to eliminate preventable deaths.”

@Masimo | #Masimo

About International Overdose Awareness Day

International Overdose Awareness Day (August 31) is the world’s largest annual campaign to end overdose, remembering those who have died and acknowledge the grief of the family and friends left behind. The campaign, which originated in Australia, raises awareness of overdose, which is one of the world’s worst public health crises, and stimulates action and discussion about evidence-based overdose prevention and drug policy. International Overdose Awareness Day spreads the message about the tragedy of drug overdose death and that drug overdose is preventable.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.7 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,8 improve CCHD screening in newborns,9 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.10-13 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,14 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll.15 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Opioid Overdose. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/opioid-overdose.
  2. BMJ Newsroom (2020). Vastly differing opioid prescribing patterns in England even in similarly deprived areas. Available at: https://www.bmj.com/company/newsroom/vastly-differing-opioid-prescribing-patterns-in-england-even-in-similarly-deprived-areas/.
  3. Prescription Opioid Data. CDC Injury Center. Centers for Disease Control and Prevention.
  4. Levy N. An international multidisciplinary consensus statement on the prevention of opioid-related harm in adult surgical patients. Anaesthesia. 2021;76:520–536.
  5. National Safety Council. Prescription opioid pain killer public opinion poll. October 2017. https://www.cdc.gov/drugoverdose/deaths/prescription/index.html
  6. Odds of Dying - Data Details. National Safety Council; Injury Facts, 4 Mar. 2021, injuryfacts.nsc.org/all-injuries/preventable-death-overview/odds-of-dying/data-details.
  7. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  8. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  9. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  10. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  11. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  12. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  13. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  14. Estimate: Masimo data on file.
  15. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Element Six Launches DNV-B14 a New Grade of Diamond for Quantum Technology Applications21.9.2021 02:01:00 EEST | Press release

Element Six, part of the De Beers Group, has launched DNV-B14™, its newest general-purpose chemical vapour deposition (CVD) quantum-grade diamond, an ideal material for quantum technologies such as magnetic field devices, RF sensors, solid-state gyroscopes and room temperature masers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005612/en/ Element Six Launches DNV-B14 a New Grade of Diamond for Quantum Technology Applications (Graphic: Business Wire) The latest solution in Element Six’s DNV™ Series, DNV-B14™ expands the company’s range of advanced materials for emerging quantum technologies. Diamond containing nitrogen-vacancy (NV) centres offers researchers a unique solid-state platform with spin qubits that can be initialised and read out at room temperature, with long qubit lifetimes. These properties stem from diamond’s unique structure and strong bonds. DNV-B14™ is designed to provide the end-user with a uniform

Bentley Systems Announces Finalists for the 2021 Going Digital Awards in Infrastructure20.9.2021 23:02:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq:BSY), the infrastructure engineering software company, today announced the finalists for the 2021 Going Digital Awards in Infrastructure. The annual awards program honors the extraordinary work of Bentley software users advancing infrastructure design, construction, and operations throughout the world. Sixteen independent jury panels selected the 57 finalists from nearly 300 nominations submitted by more than 230 organizations from 45 countries encompassing 19 categories. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005860/en/ Join us for the Year in Infrastructure series of events and Going Digital Awards in Infrastructure highlighting advancements in going digital. (Graphic: Business Wire) Winners of the student Future Infrastructure Star Challenge will also be announced. This challenge provided students from around the world a platform to develop a concept or an idea of how th

New Conviva Data Reveals How Consumers Discover Streaming Content – And the Implications for Publishers20.9.2021 19:55:00 EEST | Press release

Conviva, the intelligence cloud for streaming media, released its State of Streaming: Content Discovery report for 2021 today, revealing how consumers find new streaming content to watch. The report showed content streamed for the first time was discovered in four ways: word of mouth (59%), advertising (52%), social media (49%) and streaming service recommendations (43%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005788/en/ Conviva's State of Streaming Content Discovery (Graphic: Business Wire) “Given the incredible amount of streaming content available today, connecting viewers with content that not only piques their interest, but also resonates enough to keep them coming back for more is a significant challenge for publishers looking to identify and engage new audiences,” said Keith Zubchevich, CEO, Conviva. “By leveraging advertising, recommendations and social media to curate and promote their offerings, publi

Verimatrix To Debut New App Monitoring SaaS Service at Money 20/20 Europe20.9.2021 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced it’s scheduled to unveil a new mobile application monitoring service, an extension of its award-winning App Shield and Code Protection solutions, during this week’s Money 20/20 Europe in-person event. Taking place September 21-23 in booth D140 at RAI Amsterdam, Verimatrix’s launch of its security monitoring service for mobile applications can assist both new and existing customers in gaining the intelligence and protections needed for mission-critical apps. The new monitoring solution is available for both Verimatrix App Shield and Verimatrix Code Protection. App Shield is a no-code SaaS service that brings unprecedented cybersecurity protection to any Android or iOS app. Developers simply upload their app to the Verimatrix App Shield platform and receive a secured version that’s ready to publish to an app store, a critical las

Citi, IFC and Global Bank Partner to Finance Women’s Economic Empowerment in Panama20.9.2021 17:08:00 EEST | Press release

Citi, Global Bank and the International Finance Corporation (IFC) have partnered to provide more mortgages and Small Medium Enterprise (SME) business loans to women. The joint initiative offers a first-of-its-kind co-lending transaction of a $90 million loan ($20 million funded by Citi for three years and $70 million funded by IFC for five years) to Global Bank. The proceeds from this loan will be used for either Low Income Housing Mortgages–Hipoteca Preferencial–for women as heads of household or for women-owned and-or women-led enterprises. In addition, Global Bank will also partner with IFC Advisory Services to further enhance and develop gender-focused products and services in Panama. “It’s an honor to support groups and institutions that seek to broaden women empowerment across the region as well as to place women at the center of Panama’s recovery from the coronavirus pandemic,” said Marcelo Gorrini, Caribbean and Central America Cluster Head and Panama Citi Country Officer. “Thi

EMGA Advises Landmark US$300M Debt Raise for BTG Pactual With DFC20.9.2021 17:00:00 EEST | Press release

Emerging Markets Global Advisory Limited (EMGA), the niche investment bank focused on emerging markets, announces today a landmark Senior Debt capital raise transaction that will allow BTG Pactual to expand its small and medium-sized enterprise (SME) activities in Brazil. The US$300 million debt facility was provided by DFC and the transaction is the largest Senior Debt facility ever advised by EMGA and follows on from a US$140 million transaction completed last year with DEG and Proparco, two European development institutions. The operation comes at a time when banks world-wide are exploring new cross-border funding options to further deliver on their support to businesses affected by the COVID-19 pandemic. Commenting on the transaction, BTG Pactual’s Caio Zanette said, “BTG Pactual is very pleased with the support of EMGA on pursuing this landmark transaction that will benefit our SME activities in Brazil. We continue to develop all our activities and the funding provided by DFC will

WilsonHCG Recognized as a “Leader” in Contingent Workforce Solutions and MSP by NelsonHall20.9.2021 17:00:00 EEST | Press release

WilsonHCG has been identified as a “Leader” in NelsonHall’s 2021 NEAT Vendor Evaluation and Assessment Tool for Managed Service Program (MSP) and Contingent Workforce Services (CWS) providers. “Being ranked as a Leader for our contingent workforce services is a testament to listening to our clients’ needs and differentiating by providing a high-touch experience that’s often overlooked in this space. The team is committed to exceptional service and it shows,” said John Wilson, CEO, WilsonHCG. “Organizations are looking for a variety of talent solutions in this challenging market and we’re proud to offer contingent workforce services that give them access to the talent they need to succeed.” Nikki Edwards, Principal Research Analyst with NelsonHall’s HR Technology & Services practice, added, “WilsonHCG applies a high-touch and personalized approach to its range of next-generation contingent workforce solutions (with a broad range of service expertise and use of cutting-edge tech), enabli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom